Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.910
-0.050 (-2.55%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cellectis Employees
As of December 31, 2023, Cellectis had 221 total employees, including 216 full-time and 5 part-time employees. The number of employees decreased by 16 or -6.75% compared to the previous year.
Employees
221
Change (1Y)
-16
Growth (1Y)
-6.75%
Revenue / Employee
$163,086
Profits / Employee
-$382,253
Market Cap
182.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accuray | 987 |
InfuSystem Holdings | 516 |
ADC Therapeutics | 274 |
Sight Sciences | 214 |
Nektar Therapeutics | 137 |
BrainsWay | 134 |
Senseonics Holdings | 132 |
Profound Medical | 131 |
CLLS News
- 15 days ago - Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting - GlobeNewsWire
- 15 days ago - Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 - GlobeNewsWire
- 21 days ago - Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 - GlobeNewsWire
- 4 weeks ago - Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - GlobeNewsWire
- 2 months ago - Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety - GlobeNewsWire
- 2 months ago - Cellectis: Cheap With Promising But Speculative Cancer Therapies - Seeking Alpha
- 3 months ago - Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors - GlobeNewsWire